메뉴 건너뛰기




Volumn 32, Issue 2, 2014, Pages 83-89

Adverse event reporting in cancer clinical trial publications

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

EID: 84894864108     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.2219     Document Type: Article
Times cited : (116)

References (22)
  • 2
    • 0035906308 scopus 로고    scopus 로고
    • The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials
    • Moher D, Schulz KF, Altman D: The CONSORT statement: Revised recommendations for improving the quality of reports of parallelgroup randomized trials. JAMA 285:1987-1991, 2001 (Pubitemid 32366951)
    • (2001) Journal of the American Medical Association , vol.285 , Issue.15 , pp. 1987-1991
    • Moher, D.1    Schulz, K.F.2    Altman, D.3
  • 3
    • 0035941525 scopus 로고    scopus 로고
    • Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas
    • Ioannidis JP, Lau J: Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 285:437-443, 2001 (Pubitemid 32097262)
    • (2001) Journal of the American Medical Association , vol.285 , Issue.4 , pp. 437-443
    • Ioannidis, J.P.A.1    Lau, J.2
  • 6
    • 84865165918 scopus 로고    scopus 로고
    • The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs
    • Niraula S, Seruga B, Ocana A, et al: The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 30:3012-3019, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 3012-3019
    • Niraula, S.1    Seruga, B.2    Ocana, A.3
  • 9
    • 54849184800 scopus 로고    scopus 로고
    • Published randomized controlled trials of drug therapy for dementia often lack complete data on harm
    • Lee PE, Fischer HD, Rochon PA, et al: Published randomized controlled trials of drug therapy for dementia often lack complete data on harm. J Clin Epidemiol 61:1152-1160, 2008
    • (2008) J Clin Epidemiol , vol.61 , pp. 1152-1160
    • Lee, P.E.1    Fischer, H.D.2    Rochon, P.A.3
  • 10
    • 33947266027 scopus 로고    scopus 로고
    • Reporting adverse events in randomized controlled trials
    • DOI 10.1002/pds.1310
    • Nuovo J, Sather C: Reporting adverse events in randomized controlled trials. Pharmacoepidemiol Drug Saf 16:349-351, 2007 (Pubitemid 46431697)
    • (2007) Pharmacoepidemiology and Drug Safety , vol.16 , Issue.3 , pp. 349-351
    • Nuovo, J.1    Sather, C.2
  • 11
    • 70350489859 scopus 로고    scopus 로고
    • Reporting of safety results in published reports of randomized controlled trials
    • Pitrou I, Boutron I, Ahmad N, et al: Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 169:1756-1761, 2009
    • (2009) Arch Intern Med , vol.169 , pp. 1756-1761
    • Pitrou, I.1    Boutron, I.2    Ahmad, N.3
  • 12
    • 84905831456 scopus 로고    scopus 로고
    • Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on quality of treatment related harms reporting: An analysis of National Cancer Institute's Co-Operative Group phase III randomized controlled trials
    • abstr 673
    • Mhaskar R, Wao H, Reljic T, et al: Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on quality of treatment related harms reporting: An analysis of National Cancer Institute's Co-Operative Group phase III randomized controlled trials. Blood 118, 2011 (abstr 673)
    • (2011) Blood , vol.118
    • Mhaskar, R.1    Wao, H.2    Reljic, T.3
  • 14
    • 33748446657 scopus 로고    scopus 로고
    • Adverse event reporting in publications compared with sponsor database for cancer clinical trials
    • DOI 10.1200/JCO.2005.05.3959
    • Scharf O, Colevas AD: Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 24:3933-3938, 2006 (Pubitemid 46630741)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.24 , pp. 3933-3938
    • Scharf, O.1    Colevas, A.D.2
  • 15
    • 84875139810 scopus 로고    scopus 로고
    • Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
    • Vera-Badillo FE, Shapiro R, Ocana A, et al: Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 24:1238-1244, 2013
    • (2013) Ann Oncol , vol.24 , pp. 1238-1244
    • Vera-Badillo, F.E.1    Shapiro, R.2    Ocana, A.3
  • 16
    • 33644831407 scopus 로고    scopus 로고
    • Dealing with a deluge of data: An assessment of adverse event data on North Central Cancer Treatment Group trials
    • Mahoney MR, Sargent DJ, O'Connell MJ, et al: Dealing with a deluge of data: An assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol 23:9275-9281, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 9275-9281
    • Mahoney, M.R.1    Sargent, D.J.2    O'Connell, M.J.3
  • 17
    • 66649132782 scopus 로고    scopus 로고
    • Quality of reporting of serious adverse drug events to an institutional review board: A case study with the novel cancer agent, imatinib mesylate
    • Dorr DA, Burdon R, West DP, et al: Quality of reporting of serious adverse drug events to an institutional review board: A case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res 15:3850-3855, 2009
    • (2009) Clin Cancer Res , vol.15 , pp. 3850-3855
    • Dorr, D.A.1    Burdon, R.2    West, D.P.3
  • 19
    • 39649101923 scopus 로고    scopus 로고
    • Is there room for improvement in adverse event reporting in the era of targeted therapies?
    • DOI 10.1093/jnci/djm324
    • Edgerly M, Fojo T: Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 100:240-242, 2008 (Pubitemid 351480535)
    • (2008) Journal of the National Cancer Institute , vol.100 , Issue.4 , pp. 240-242
    • Edgerly, M.1    Fojo, T.2
  • 20
    • 84870720349 scopus 로고    scopus 로고
    • Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology
    • Basch E, Abernethy AP, Mullins CD, et al: Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 30:4249-4255, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 4249-4255
    • Basch, E.1    Abernethy, A.P.2    Mullins, C.D.3
  • 21
    • 56649123212 scopus 로고    scopus 로고
    • Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis
    • Nalluri SR, Chu D, Keresztes R, et al: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 300:2277-2285, 2008
    • (2008) JAMA , vol.300 , pp. 2277-2285
    • Nalluri, S.R.1    Chu, D.2    Keresztes, R.3
  • 22
    • 79551520348 scopus 로고    scopus 로고
    • Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis
    • Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 305:487-494, 2011
    • (2011) JAMA , vol.305 , pp. 487-494
    • Ranpura, V.1    Hapani, S.2    Wu, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.